[go: up one dir, main page]

WO2002007713A3 - Medicaments containing cilansetron for treating non-obstipated male ibs patients - Google Patents

Medicaments containing cilansetron for treating non-obstipated male ibs patients Download PDF

Info

Publication number
WO2002007713A3
WO2002007713A3 PCT/EP2001/008260 EP0108260W WO0207713A3 WO 2002007713 A3 WO2002007713 A3 WO 2002007713A3 EP 0108260 W EP0108260 W EP 0108260W WO 0207713 A3 WO0207713 A3 WO 0207713A3
Authority
WO
WIPO (PCT)
Prior art keywords
obstipated
treating non
medicaments containing
ibs patients
cilansetron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/008260
Other languages
German (de)
French (fr)
Other versions
WO2002007713A2 (en
Inventor
Werner Cautreels
Claus Rudolf Steinborn
Heinz Guenter Krause
Steven David Caras
Egbertus Hendrikus Biesheuvel
Albertus Hermannus Plekkenpol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10123447A external-priority patent/DE10123447A1/en
Priority to EP01954044A priority Critical patent/EP1307195A2/en
Priority to SK127-2003A priority patent/SK1272003A3/en
Priority to BR0112690-3A priority patent/BR0112690A/en
Priority to KR10-2003-7000038A priority patent/KR20030019951A/en
Priority to MXPA02012917A priority patent/MXPA02012917A/en
Priority to IL15397201A priority patent/IL153972A0/en
Priority to AU2001276409A priority patent/AU2001276409A1/en
Priority to JP2002513449A priority patent/JP2004504343A/en
Priority to CA002417677A priority patent/CA2417677A1/en
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Priority to HU0301479A priority patent/HUP0301479A2/en
Publication of WO2002007713A2 publication Critical patent/WO2002007713A2/en
Publication of WO2002007713A3 publication Critical patent/WO2002007713A3/en
Priority to NO20030373A priority patent/NO20030373D0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of cilansetron for treating non-obstipated male IBS patients and also for treating patients of both sexes, who suffer from irritable bowel syndrome (IBS), by administering the pharmaceutical preparation three times a day. In said preparation, alosetron, azasetron, dolasetron, granisetron, indisetron, itasetron, lerisetron, ondansetron, ramosetron, tropisetron, and/or (R)-zacopride are used as 5HT3 receptor antagonists.
PCT/EP2001/008260 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male ibs patients Ceased WO2002007713A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
HU0301479A HUP0301479A2 (en) 2000-07-26 2001-07-18 Use of cilansetron for producing pharmaceutical compositions for treating non-obstipated male ibs patients
AU2001276409A AU2001276409A1 (en) 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male ibs patients
BR0112690-3A BR0112690A (en) 2000-07-26 2001-07-18 Cilansetron-containing drug for the treatment of non-constipative male ibs patients
KR10-2003-7000038A KR20030019951A (en) 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male ibs patients
MXPA02012917A MXPA02012917A (en) 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male ibs patients.
IL15397201A IL153972A0 (en) 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male ibs patients
JP2002513449A JP2004504343A (en) 2000-07-26 2001-07-18 Silanesetron-containing drugs for the treatment of non-constipated male IBS patients
EP01954044A EP1307195A2 (en) 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male ibs patients
CA002417677A CA2417677A1 (en) 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male ibs patients
SK127-2003A SK1272003A3 (en) 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male IBS patients
NO20030373A NO20030373D0 (en) 2000-07-26 2003-01-24 Medicines containing cilantrone for the treatment of non-constipated male IBS patients

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10036645.7 2000-07-26
DE10036645 2000-07-26
DE10123447A DE10123447A1 (en) 2000-07-26 2001-05-14 Cilansetron-containing medicines for the treatment of non-obstipative male IBS patients
DE10123447.3 2001-05-14

Publications (2)

Publication Number Publication Date
WO2002007713A2 WO2002007713A2 (en) 2002-01-31
WO2002007713A3 true WO2002007713A3 (en) 2002-11-14

Family

ID=26006529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008260 Ceased WO2002007713A2 (en) 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male ibs patients

Country Status (16)

Country Link
EP (1) EP1307195A2 (en)
JP (1) JP2004504343A (en)
CN (1) CN1444479A (en)
AR (1) AR028970A1 (en)
AU (1) AU2001276409A1 (en)
BR (1) BR0112690A (en)
CA (1) CA2417677A1 (en)
CZ (1) CZ2003158A3 (en)
HU (1) HUP0301479A2 (en)
IL (1) IL153972A0 (en)
MX (1) MXPA02012917A (en)
NO (1) NO20030373D0 (en)
PL (1) PL363517A1 (en)
RU (1) RU2003104798A (en)
SK (1) SK1272003A3 (en)
WO (1) WO2002007713A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
MXPA05009025A (en) * 2004-01-30 2006-04-27 Astellas Pharma Inc Therapeutic agent for diarrhea-type irritable bowel syndrome.
WO2005073220A1 (en) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Remedy for irritable bowel syndrome with diarrhea
JP4632204B2 (en) * 2005-09-21 2011-02-16 アステラス製薬株式会社 Antidiarrheal irritable bowel syndrome treatment
US7662831B2 (en) 2006-07-27 2010-02-16 Wyeth Llc Tetracyclic indoles as potassium channel modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017755A2 (en) * 1997-10-07 1999-04-15 Glaxo Group Limited Medicaments
WO2001045685A2 (en) * 1999-12-20 2001-06-28 Glaxo Group Limited Formulations of adenosine a1 agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017755A2 (en) * 1997-10-07 1999-04-15 Glaxo Group Limited Medicaments
WO2001045685A2 (en) * 1999-12-20 2001-06-28 Glaxo Group Limited Formulations of adenosine a1 agonists

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Irritable bowel syndrome - Cilansetron.", MANUFACTURING CHEMIST, (2000) 71/2 (22)., XP001042043 *
BEGLINGER, C. (1) ET AL: "Effect of cilansetron, a specific 5-HT-3 receptor antagonist, on gastrointestinal motor function in normal subjects.", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, (1996) VOL. 353, NO. 4 SUPPL., PP. R163. MEETING INFO.: 37TH SPRING MEETING OF THE GERMAN SOCIETY FOR EXPERIMENTAL AND CLINICAL PHARMACOLOGY AND TOXICOLOGY MAINZ, GERMANY MARCH 12-14, 1996, XP001058426 *
BOTELLA, A. ET AL: "Intracolonic glycerol induces abdominal contractions in rats: role of 5-HT3 receptors", FUNDAM. CLIN. PHARMACOL. (1998), 12(6), 619-623, XP001058254 *
RABASSEDA, X. ET AL: "Cilansetron", DRUGS FUTURE (1999), 24(5), 475-482, XP001058216 *
STACHER, GEORG ET AL: "Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial", BR. J. CLIN. PHARMACOL. (2000), 49(5), 429-436, XP001058300 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators

Also Published As

Publication number Publication date
AU2001276409A1 (en) 2002-02-05
CA2417677A1 (en) 2003-01-27
AR028970A1 (en) 2003-05-28
RU2003104798A (en) 2004-06-27
CN1444479A (en) 2003-09-24
HUP0301479A2 (en) 2003-09-29
IL153972A0 (en) 2003-07-31
PL363517A1 (en) 2004-11-29
CZ2003158A3 (en) 2003-08-13
NO20030373L (en) 2003-01-24
BR0112690A (en) 2003-06-24
WO2002007713A2 (en) 2002-01-31
NO20030373D0 (en) 2003-01-24
MXPA02012917A (en) 2003-05-14
SK1272003A3 (en) 2003-07-01
EP1307195A2 (en) 2003-05-07
JP2004504343A (en) 2004-02-12

Similar Documents

Publication Publication Date Title
NZ503698A (en) 5-Hydroxytryptamine (5-HT) receptor antagonists for use in the treatment of inflammatory bowel syndrome (IBS)
WO2009016564A3 (en) 2-aza-bicyclo[3.3.0]octane derivatives
MX2010008993A (en) 2-aza-bicyclo[2.2.1]heptane derivatives.
CR7548A (en) DERIVATIVES OF TRIAZOLE AS ANTAGONISTS OF THE TACHYKININ RECEIVER
WO2003063800A8 (en) 8-heteroaryl xanthine adenosine a2b receptor antagonists
WO2002007713A3 (en) Medicaments containing cilansetron for treating non-obstipated male ibs patients
NO20071718L (en) Use of the A2B adenosine receptor antagonist to cure ulcers
TW200833328A (en) 2-aza-bicyclo[3.1.0]hexane derivatives
AU1192302A (en) Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists
PL378136A1 (en) Hiv replication inhibiting pyrimidines and triazines
TN2011000282A1 (en) Alkaloid aminoester derivatives and medicinal composition thereof
WO2005000820A3 (en) 4-cyanopyrazole-3-carboxamide derivatives preparation and application thereof as cb1 cannabinoid antagonists
WO2008070313A3 (en) 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
MX2009005174A (en) 5-sulfanylmethyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists.
CL2011002103A1 (en) Compounds derived from indazole; preparation procedure; intermediate compound; pharmaceutical composition and combination that includes them; and use to treat a condition for which a ccr4 receptor antagonist is indicated.
WO2006031513A3 (en) Aryl spirolactam cgrp receptor antagonists
AU2003287914A8 (en) Piperidine and pyrrolidine derivatives as antagonists of histamine h3 receptor
DOP2012000143A (en) PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINO-2- [1- (2-FLUOROBENCIL) -1H-PIRAZOLO [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} CARBAMATO DE METTILO AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE
WO2010033198A3 (en) Analogs of indole-3-carbinol and their use as agents against infection
MX356478B (en) 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazo l-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist.
WO2004000840A3 (en) Quinuclidine derivatives and pharmaceutical compositions containing the same
CO6210822A2 (en) DERIVATIVES OF AMINA AND ITS USE IN DISEASES MEDIATED BY THE BETA 2 ADRENORECEPTOR
AU2020278236B2 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
WO2008099186A8 (en) Heterocyclic derivatives as m3 muscarinic receptors
WO2011138265A3 (en) Indole and indazole derivatives as orexin receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012917

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020037000038

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 153972

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200300445

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PV2003-158

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 01813307X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2417677

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001954044

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1272003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 523959

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001276409

Country of ref document: AU

Ref document number: 198/MUMNP/2003

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2003104798

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWP Wipo information: published in national office

Ref document number: 1020037000038

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001954044

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-158

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2003-158

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001954044

Country of ref document: EP